Subscribe
L-R: Michael Specht, Daniel Block.
3 April 2025NewsAmericasMarisa Woutersen

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant

The IP specialist bypassed vendors and turned to its own ‘tech geeks’ to create an in-house AI solution for drafting patent applications. LSIPR meets the attorney coders doing it for themselves.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis and MSN feud intensifies after Fed Circ denies rehearing
27 March 2025   Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024   Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen at LSPN Fall North America.
Biotechnology
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
25 July 2024   AI has the potential to revolutionise patent examination but uneven adoption of the technology could undermine fairness in the system, says Matthew Veale of Patsnap.


Editor's picks

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025

Editor's picks

Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025

More on this story

Americas
Novartis and MSN feud intensifies after Fed Circ denies rehearing
27 March 2025   Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024   Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen at LSPN Fall North America.
Biotechnology
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
25 July 2024   AI has the potential to revolutionise patent examination but uneven adoption of the technology could undermine fairness in the system, says Matthew Veale of Patsnap.

More on this story

Americas
Novartis and MSN feud intensifies after Fed Circ denies rehearing
27 March 2025   Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024   Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen at LSPN Fall North America.
Biotechnology
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
25 July 2024   AI has the potential to revolutionise patent examination but uneven adoption of the technology could undermine fairness in the system, says Matthew Veale of Patsnap.

More features

Fed Circ: Generic doesn’t infringe Metacel MS drug
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
Strategic IP protection for biotech-related GenAI
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
In vivo cell therapy: A world beyond ex vivo engineering
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency